Table 4:
Association between diuretic prescription and extracellular volume outcomes, restricted to patients with dialysis vintage <1 year.
| Variables | n (%) | Pre-dialysis SBP (mmHg) | Pre-dialysis DBP (mmHg) | IDWG (kg) | RUV (as >200 ml/24 h) |
|---|---|---|---|---|---|
| Patients, n | 29 934 | 29 923 | 27 538 | 31 621 | |
| Mean (SD) | 143.9 (22.55) | 75.14 (13.62) | 2.49 (3.31) | ||
| Events, n | 8382 | ||||
| Prevalence of outcome, % | 26.5 | ||||
| Patient diuretic use, mean (95% CI) | |||||
| Yes | 38.2 | 1 (0.4–1.5) | −0.2 (−0.5–0.1) | −0.09 (−0.18 to −0.01) | 1.51 (1.41–1.61) |
| No | 61.8 | 0 (Ref.) | 0 (Ref.) | 0 (Ref.) | 1 (Ref.) |
| Patient loop diuretic dose (mg/day), mean (95% CI) | |||||
| No dose | 72.3 | 0 (Ref.) | 0 (Ref.) | 0 (Ref.) | 1 (Ref.) |
| 0–≤60 | 7.5 | 1.2 (0.1–2.2) | −0.3 (−0.9–0.3) | −0.3 (−0.47 to −0.13) | 1.5 (1.34–1.68) |
| 60–≤200 | 10.1 | 0.2 (−0.8–1.1) | −0.7 (−1.2, -0.2) | −0.11 (−0.26–0.04) | 1.59 (1.43–1.76) |
| >200 | 10.2 | 0.6 (−0.5–1.7) | −0.4 (−1–0.2) | −0.01 (−0.19–0.16) | 1.59 (1.42–1.78) |
Mean difference (95% CI) or odds ratio (95% CI) of each outcome shown for diuretic use (yes versus no) and loop diuretic dose (reference group: no dose). Doses of torsemide (4:1) and bumetanide (80:1) were converted to oral furosemide-equivalent doses. Linear mixed models (for SBP, DBP and IDWG) and logistic regression models (for RUV) adjusted for DOPPS phase, country, age, sex, Black race, <90 days dialysis vintage, catheter use, BMI, serum albumin, haemoglobin and 13 comorbidities.